ZA201408967B - Solubilized capsule formulation of 1,1-dimethyl[(1s)-1-{[(2s,4r)-4-(chloro-4methoxyisoquinolin-1-yloxy)-2-({1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate - Google Patents

Solubilized capsule formulation of 1,1-dimethyl[(1s)-1-{[(2s,4r)-4-(chloro-4methoxyisoquinolin-1-yloxy)-2-({1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate

Info

Publication number
ZA201408967B
ZA201408967B ZA2014/08967A ZA201408967A ZA201408967B ZA 201408967 B ZA201408967 B ZA 201408967B ZA 2014/08967 A ZA2014/08967 A ZA 2014/08967A ZA 201408967 A ZA201408967 A ZA 201408967A ZA 201408967 B ZA201408967 B ZA 201408967B
Authority
ZA
South Africa
Prior art keywords
carbamoyl
ethenylcyclopropyl
cyclopropylsulfonyl
dimethylpropyl
yloxy
Prior art date
Application number
ZA2014/08967A
Other languages
English (en)
Inventor
Robert Kevin Perrone
Original Assignee
Britol-Myers Squibb Holdings Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201408967(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Britol-Myers Squibb Holdings Ireland filed Critical Britol-Myers Squibb Holdings Ireland
Publication of ZA201408967B publication Critical patent/ZA201408967B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2014/08967A 2012-05-07 2014-12-05 Solubilized capsule formulation of 1,1-dimethyl[(1s)-1-{[(2s,4r)-4-(chloro-4methoxyisoquinolin-1-yloxy)-2-({1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate ZA201408967B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261643454P 2012-05-07 2012-05-07
PCT/US2013/038770 WO2013169520A1 (en) 2012-05-07 2013-04-30 Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate

Publications (1)

Publication Number Publication Date
ZA201408967B true ZA201408967B (en) 2016-10-26

Family

ID=48428670

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/08967A ZA201408967B (en) 2012-05-07 2014-12-05 Solubilized capsule formulation of 1,1-dimethyl[(1s)-1-{[(2s,4r)-4-(chloro-4methoxyisoquinolin-1-yloxy)-2-({1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate

Country Status (33)

Country Link
US (1) US20130302414A1 (https=)
EP (1) EP2846780B1 (https=)
JP (1) JP6276756B2 (https=)
KR (1) KR20150004921A (https=)
CN (1) CN104363899A (https=)
AR (1) AR090954A1 (https=)
AU (1) AU2013260005B2 (https=)
BR (1) BR112014027676A2 (https=)
CA (1) CA2872765A1 (https=)
CL (1) CL2014003012A1 (https=)
CO (1) CO7141457A2 (https=)
CY (1) CY1120756T1 (https=)
DK (1) DK2846780T3 (https=)
EA (1) EA028749B1 (https=)
ES (1) ES2688817T3 (https=)
HR (1) HRP20181583T1 (https=)
IL (1) IL235466B (https=)
LT (1) LT2846780T (https=)
MX (1) MX358545B (https=)
MY (1) MY171378A (https=)
NZ (1) NZ630248A (https=)
PE (1) PE20142439A1 (https=)
PH (1) PH12014502405A1 (https=)
PL (1) PL2846780T3 (https=)
PT (1) PT2846780T (https=)
RS (1) RS57881B1 (https=)
SG (1) SG11201406964QA (https=)
SI (1) SI2846780T1 (https=)
SM (1) SMT201800506T1 (https=)
TW (1) TWI577392B (https=)
UY (1) UY34785A (https=)
WO (1) WO2013169520A1 (https=)
ZA (1) ZA201408967B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2673870T3 (es) * 2012-05-07 2018-06-26 Bristol-Myers Squibb Holdings Ireland Formulación de dosificación oral sólida de [(1S)-1-{[(2S,4R)-4-(7-cloro-4-metoxiisoquinolin-1-iloxi)-2-({(1R,2S)-1-[(ciclopropilsulfonil) carbamoil]-2-etenilciclopropil} carbamoil) pirrolidin-1-il] carbonil}-2,2-dimetil-propil] carbamato de 1,1-dimetiletilo
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
WO2019130341A1 (en) * 2017-12-26 2019-07-04 Hetero Labs Limited Capsule compositions comprising lopinavir and ritonavir
AU2019233606B2 (en) 2018-03-14 2024-10-03 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual NK-1/NK-3 receptor antagonists
FI3897589T3 (fi) * 2018-12-19 2026-01-13 Corcept Therapeutics Inc Farmaseuttisia formulaatioita, jotka sisältävät relakorilanttia, heteroaryyliketonifusoitua atsekaliiniyhdistettä
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
DE60132103T2 (de) * 2000-10-31 2008-04-17 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Perorale, selbst-emulgierende darreichungsformen von pyranon-proteaseinhibitoren
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20110229438A1 (en) * 2008-10-09 2011-09-22 Anadys Pharmaceuticals, Inc. Method of inhibiting hepatitus c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Also Published As

Publication number Publication date
PH12014502405A1 (en) 2015-01-12
SMT201800506T1 (it) 2018-11-09
AU2013260005A1 (en) 2015-01-15
CN104363899A (zh) 2015-02-18
DK2846780T3 (en) 2018-09-17
MY171378A (en) 2019-10-10
HK1204552A1 (en) 2015-11-27
SI2846780T1 (sl) 2018-09-28
SG11201406964QA (en) 2014-11-27
IL235466B (en) 2019-03-31
UY34785A (es) 2013-11-29
JP6276756B2 (ja) 2018-02-07
EP2846780B1 (en) 2018-07-18
PE20142439A1 (es) 2015-01-28
CO7141457A2 (es) 2014-12-12
LT2846780T (lt) 2018-11-12
ES2688817T3 (es) 2018-11-07
KR20150004921A (ko) 2015-01-13
PL2846780T3 (pl) 2018-11-30
HRP20181583T1 (hr) 2018-11-30
RS57881B1 (sr) 2019-01-31
MX358545B (es) 2018-08-24
TW201350145A (zh) 2013-12-16
MX2014013220A (es) 2015-05-11
CL2014003012A1 (es) 2015-07-10
EA201492039A1 (ru) 2015-02-27
TWI577392B (zh) 2017-04-11
JP2015516418A (ja) 2015-06-11
CY1120756T1 (el) 2019-12-11
EA028749B1 (ru) 2017-12-29
NZ630248A (en) 2016-11-25
AR090954A1 (es) 2014-12-17
EP2846780A1 (en) 2015-03-18
CA2872765A1 (en) 2013-11-14
BR112014027676A2 (pt) 2017-06-27
PT2846780T (pt) 2018-10-26
US20130302414A1 (en) 2013-11-14
AU2013260005B2 (en) 2017-07-13
WO2013169520A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
ZA201408967B (en) Solubilized capsule formulation of 1,1-dimethyl[(1s)-1-{[(2s,4r)-4-(chloro-4methoxyisoquinolin-1-yloxy)-2-({1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
WO2013152059A8 (en) Multicolored ph-activatable fluorescence nanoplatform
MX346113B (es) Polimorfos de n-(2-metoxibenzoil)-4-[(metilaminocarbonil)amino]ben cenosulfonamida.
IL235654A (en) Pharmaceutical Composition Containing (1r, 4r) - 6 '- Fluoro - n, n - Dimethyl - 4 - Phenyl - 4', 9 '- Dihydro - 3'h - Spiro [Cyclohexane - 1, 1' - Pirano [3, 4 , b] indole] - 4 - reliable and anticonvulsant drug
MX356245B (es) Composicion farmaceutica que comprende (1r,4r)-6´-fluoro-n,n-dimet il-4-fenil-4´,9´-dihidro-3'h-espiro[ciclohexan-1,1´-pirano[3,4,b] indol]-4-amina y un gabapentinoide.
IL235657B (en) Pharmacy device containing (1r, 4r) - 6' - fluoro - n, n - dimethyl - 4 - phenyl - 4', 9' - dihydro - 3'h - spiro [cyclohexane - 1, 1' - pyrano [3, 4 ,b] indole] – 4 – amine and antidepressants
IL235653B (en) A pharmaceutical preparation containing (1r, 4r) - 6' - fluoro - n, n - dimethyl - 4 - phenyl - 4', 9' - dihydro - 3'h - spiro [cyclohexane - 1, 1' - pyrano [3, 4 ,b] indole] – 4 – amine and a non-steroidal anti-rheumatic drug
BR112014028569A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n , n-dimetil-4 ,9-di-hidro-3h-espiro[ciclo-hexano-1 ,1-pirano-[3,4,b]indol]-4-amina e um oxicam
TH1401006625A (th) สูตรผสมแคปซูลที่ละลายได้ของ 1,1-ไดเมธิลเอธิล[(1s)-1{[2s,4r)-4-(7-คลอโร-4เมธอกซีไอโซควิโนลิน-1-อิลออกซี)-2-({1r,2s)-1-[(ไซโคลโพรพิลซัลโฟนิล) คาร์บาโมอิล]-2-เอธีนิลไซโคลโพรพิล}คาร์บาโมอิล)ไพร์โรลิดิน-1-อิล]คาร์บอนิล}-2,2-ไดเมธิลโพรพิล]คาร์บาเมต
EP2890368A4 (en) RECIPE FOR A DOUBLE-LAYER COMPOSITE TABLET WITH ATORVASTATIN, IRBESARTAN AND MAGNESIUM CARBONATE
IL235651B (en) A pharmaceutical preparation containing (1r, 4r) - 6' - fluoro - n, n - dimethyl - 4 - phenyl - 4', 9' - dihydro - 3'h - spiro [cyclohexane - 1, 1' - pyrano [3, 4 ,b] Indole] - 4 - amine and paracetamol or propacetamol
BR112014028564A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n , n-dimetil-4 ,9-di-hidro-3h-espiro[ciclo-hexano-1 ,1-pirano-[3,4,b]indol]-4-amina e um componente de ácido salicílico
BR112014028557A2 (pt) composição farmacêutica compreendendo ( 1r , 4r )-6-fluoro-n ,n-dimetil-4-fenil-4 ,9-di-hidro-3h-espiro[ciclohexano-1 ,1-pirano-[3,4,b]indol]-4- amina e um anticonvulsivo
TH156288A (th) สูตรผสมแคปซูลที่ละลายได้ของ 1,1-ไดเมธิลเอธิล[(1s)-1{[2s,4r)-4-(7-คลอโร-4เมธอกซีไอโซควิโนลิน-1-อิลออกซี)-2-({1r,2s)-1-[(ไซโคลโพรพิลซัลโฟนิล) คาร์บาโมอิล]-2-เอธีนิลไซโคลโพรพิล}คาร์บาโมอิล)ไพร์โรลิดิน-1-อิล]คาร์บอนิล}-2,2-ไดเมธิลโพรพิล]คาร์บาเมต
HK1218512A1 (zh) 雜環化合物和其用途
ZA201105275B (en) Pharmaceutical formulation containing atorvastatin and method for the preparation thereof